Pharmafile Logo

service design

- PMLiVE

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Wilmington Healthcare

- PMLiVE

CureVac to acquire Frame Cancer Therapeutics in €32m deal

The acquisition will advance CureVac’s oncology strategy and offers the potential to develop off-the-shelf and personalised cancer vaccines

Part 3 of the Medscape video series #EHA

Ahead of  Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr. Naval Daver on the most important abstracts to look out for in Myeloid and...

Medscape Education Global

Part 2 of the Medscape video interview series

Ahead of Europe’s largest haematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer interviews Dr. John Gribben on the most important abstracts to look out for in CLL and the...

Medscape Education Global

How scientific storytelling can help Pharma cut through the noise

Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...

Page & Page and Partners

- PMLiVE

FDA limits use of Janssen’s COVID-19 vaccine

Authorisation of Janssen COVID-19 vaccine restricted among certain people following analysis and evaluation

- PMLiVE

EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES

As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...

Wilmington Healthcare

- PMLiVE

Gilead signs $300m deal with Dragonfly to advance immunotherapies

The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities

- PMLiVE

Cancer Research UK drives innovation with Cancer Research Horizons

Industry partners will gain access to an extensive network of 4,000 world-leading cancer researchers

- PMLiVE

Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara

The biosimilar was seen to have no clinically meaningful differences to Stelara

Onyx Health Joins Forces with Rare Disease Specialists Actigen

Onyx Health will be working with Actigen to raise awareness of their innovative clinical trial work in rare diseases and the need to develop new treatment solutions.

Onyx Health

- PMLiVE

UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS

Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...

Wilmington Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links